Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
B. Gerber(University of Zurich), Georg Stüssi(Institute of Oncology Research), Barbara Jeker(University of Bern), Erika Lerch(Institute of Oncology Research), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Felicitas Hitz(Kantonsspital St. Gallen), Martina Kleber(University Hospital of Basel), Helen Baldomero(University Hospital of Basel), Antonia Müller(University Hospital of Zurich), Guido Ghilardi(Hospital of the University of Pennsylvania), Thomas Pabst(University Hospital of Bern), Michele Ghielmini(Institute of Oncology Research), Urs Schanz(University Hospital of Zurich), Luciano Wannesson(Università della Svizzera italiana), Rouven Müller(University Hospital of Lausanne), Mario Bargetzi(Kantonsspital Aarau), Dominik Heim(University Hospital of Basel), Anne Cairoli(University Hospital of Lausanne), Panagiotis Samaras(University Hospital of Zurich), Jakob Passweg(University Hospital of Basel), Adrian Schmidt(Triemli Hospital)
Cited by 20
Related Papers
Solid Cancers after Bone Marrow Transplantation
|New England Journal of Medicine|1997|968
One million haemopoietic stem-cell transplants: a retrospective observational study
|The Lancet Haematology|2015|434
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378